Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1458-1465

  Shi, Yi ^a   Gao, Ping ^a   Gong, Yuchuan ^a   Ping, Haili ^b  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

biorevelant dissolution; biphasic; Celecoxib; flow cell; in vitro dissolution; partition; poorly soluble drug; USP II apparatus; USP IV dissolution

Indexed keywords

ALCOHOL; BUFFER; CELECOXIB; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 400; OCTANOL; OLEIC ACID; POLYSORBATE 80; POVIDONE; TROMETAMOL;

ANALYTIC METHOD; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; PARTITION COEFFICIENT; PRIORITY JOURNAL; SYSTEMIC CIRCULATION;

CAPSULES; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; OCTANOLS; PYRAZOLES; SOLUBILITY; SOLVENTS; SULFONAMIDES; WATER;

EID: 77957739104     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100114a     Document Type: Article

References (29)

1. Gray, V.; Kelly, G.; Xia, M.; Butley, C.; Thomas, S.; Mayock, S. The sciences of USP 1 and 2 dissolution: present challenges and future relevance Pharm. Res. 2009, 26 (6) 1289-1302
2. Azarmi, S.; Roa, W.; Lobenberg, R. Current perspectives in dissolution testing of conventional and novel dosage forms Int. J. Pharm. 2007, 328, 12-21
3. Niebergall, P. J.; Patil, M. Y.; Sugita, E. T. Simultaneous determination of dissolution and partitioning rates in vitro J. Pharm. Sci. 1967, 56 (8) 943-947
4. Gibaldi, M.; Feldman, S. Establishment of sink conditions in dissolution rate determinations: Theoretical considerations and application to nondisintegegrating dosage forms J. Pharm. Sci. 1967, 56 (10) 1238-1242
5. Niebergall, P. J.; Sugita, E.; Schnaare, R. L. Dissolution rates under sink conditions J. Pharm. Sci. 1971, 60 (10) 1575-1576
6. Stead, J. A.; Freeman, M.; John, E. G.; Ward, G. T.; Whiting, B. Ibuprofen tablets: dissolution and bioavailabilities Int. J. Pharm. 1983, 14, 59-72
7. Kinget, R.; Greef, H. D. In vitro assessment of drug release from semi-solid lipid matrices Eur. J. Pharm. Sci. 1995, 3, 105-111
8. Hoa, N. T.; Kinget, R. Design and evaluation of two-phase partition-dissolution method and its use in evaluating artemisinin tablets J. Pharm. Sci. 1996, 85 (10) 1060-1063
9. Ngo, T. H.; Quintens, I.; Roest, E.; Declerck, P. J.; Hoogmartens, J. Bioavailability of different artemisinin tablet formulations in rabbit plasma-correlation with results obtained by an in vitro dissolution J. Pharm. Biomed. Anal. 1997, 16, 185-189
10. Grundy, J. S.; Anderson, K. E.; Rogers, J. A.; Foster, R. T. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test J. Controlled Release 1997, 48, 1-8
11. Grundy, J. S.; Anderson, K. E.; Rogers, J. A.; Foster, R. T. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation using a two-phase dissolution test J. Controlled Release 1998, 55, 45-55
12. Pillay, V.; Fassihi, R. A new method for dissolution studies of lipid-filled capsules employing nifedipine as a model drug Pharm. Res. 1999, 16 (2) 333-337
13. Gabriels, M.; Plaizier-Vercammen, J. Design of a dissolution system for the evaluation of the release rate characteristics of artemether and dihydroartemisinin from tablets Int. J. Pharm. 2004, 274, 245-260
14. Vangani, S.; Li, X.; Zhou, P.; Del-Barrio, M.; Chiu, R.; Cauchon, N.; Gao, P.; Medina, C.; Jasti, B. Dissolution of poorly water-soluble drugs in biphasic media using USP 4 and fiber optic system Clin. Res. Regul. Aff. 2009, 26 (1-2) 8-19
15. Fini, A.; Orienti, I.; Tartarini, A.; Rodrigues, L.; Zecchi, V. Three phase dissolution-partition of some non-steroidal anti-inflammatory drugs Acta Pharm. Technol. 1986, 32 (2) 86-88
16. Physician Desk Reference, under Celebrex.
17. Susan, K.; Paulson, Margaret, B.; Vaughn, Susan, M.; Jessen, Yvette, Lawal; Christopher, J.; Gresk, Bo Yan; Timothy, J.; Maziasz, Chyung S., Cook; Aziz, Karim. Pharmacokinetics of Celecoxib after Oral Administration in Dogs and Humans: Effect of Food and Site of Absorption J. Pharmacol. Exp. Ther. 2001, 297 (2) 638-645
18. Lu, G. W.; Hawley, M.; Smith, M.; Geiger, B. M.; Pfund, W. Characterization of novel polymorphic form of celecoxib J. Pharm. Sci. 2006, 95 (2) 305-317
19. Dolenc, A.; Kristl, J.; Baumgartner, S.; Planinsek, O. Advantages of celecoxib nanosuspension formulation and tranformation into tablets Int. J. Pharm. 2009, 376, 204-212
20. Remenar, J. F. Improving oral bioavailability through inhibition of crystallization after dosing Am. Pharm. Rev. 2007, 10 (1) 84-89
21. Karim, A.; Brugger, A. M.; Gao, P.; Hassan, F.; Forbes, J. C. Use of a celecoxib composition for fast pain relief. US Patent 6,579,895 B2.
22. Gao, P.; Hageman, M. J.; Morozowich, W.; Dalga, R. J.; Stefanski, K. J.; Huang, T.; Karim, A.; Hassan, F.; Forbes, J. C. Pharmaceutical composition having reduced tendency for drug crystallization. WO 02/056878 A3.
23. Babu, G. V. M.; Shankar, V. G.; Sankar, K. H. Development of dissolution medium for a poorly water soluble drug, celecoxib Indian J. Pharm. Sci. 2002, 64 (6) 509-610
24. Gao, P.; Rush, R. D.; Pfund, W. P.; Huang, T.; Bauer, J. M.; Morozowich, W.; Kuo, M.; Hageman, M. J. Development of a supersaturatable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J. Pharm. Sci. 2003, 92 (12) 2395-2407
25. Gao, P.; Morozowich, W. Development of Supersaturatable SEDDS (S-SEDDS) Formulations for Improving the Oral Absorption of Poorly Soluble Drugs Expert Opin. Drug Delivery 2005, 3, 97-110
26. Design and development of a new class of supersaturatable SEDDS with potential for enhanced oral absorption and reduced GI side effects. P. Gao, W.Morozowich. Chapter in Lipid based formulations for oral drug delivery: Enhancing the bioavailability of poorly water-soluble drugs; Hauss, D. J., Ed.; Marcell Dekker: New York, 2007.
27. Poelma, F. G. J.; Breas, R.; Tukker, J. J.; Josef, J. Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat Pharm. Res. 1990, 7 (4) 392-397
28. Poelma, F. G. J.; Breas, R.; Tukker, J. J.; Crommelin, D. J. A. Intestinal absorption of drugs. The influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat J. Pharm. Pharmacol. 1991, 43 (5) 317-324
29. Chiu, Y. Y.; Higaki, K.; Neudeck, B. L.; Barnett, J. L.; Welage, L. S.; Amidon, G. L. Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells Pharm. Res. 2003, 20 (5) 749-756